Table 1.
Demographic and clinical characteristics of White postmenopausal breast cancer survivors.
| Characteristics | Overall (N = 1049) N (%) |
AIAA (N = 543) N (% within each category) |
P-value |
|---|---|---|---|
| Age, years (mean ± standard deviation) | 63.0 ± 9.8 | 60.9 ± 9.0 | <0.001 |
| Educational Level | 0.003 | ||
| High school or less | 176 (16.8) | 73 (41.5) | |
| Some college or above | 869 (83.2) | 469 (54.0) | |
| Body mass index, kg/m2 | 0.19 | ||
| <25 | 442 (42.2) | 236 (53.4) | |
| 25 to 30 | 313 (29.8) | 168 (53.7) | |
| >30 | 294 (28.0) | 139 (47.3) | |
| Reasons for menopause | 0.002 | ||
| Natural | 607 (58.2) | 290 (47.8) | |
| Induced | 435 (41.8) | 251 (57.7) | |
| Years since last menstrual period | <0.001 | ||
| >10 | 557 (54.0) | 245 (44.0) | |
| 5 to 10 | 257 (24.9) | 150 (58.4) | |
| <5 | 218 (21.1) | 142 (65.1) | |
| Cancer stage | 0.29 | ||
| 0 and I | 541 (52.1) | 267 (49.4) | |
| II | 373 (36.0) | 202 (54.2) | |
| III | 123 (11.9) | 67 (54.5) | |
| Chemotherapy | <0.001 | ||
| Yes | 558 (53.2) | 318 (57.0) | |
| No | 491 (46.8) | 225 (45.8) | |
| Tamoxifen use prior to starting AIs | 0.14 | ||
| Yes | 260 (24.8) | 145 (55.8) | |
| No | 789 (75.2) | 398 (50.4) | |
| AI type | 0.07 | ||
| Anastrozole (Arimidex) | 811 (78.7) | 421 (51.9) | |
| Exemestane (Aromasin) | 71 (6.9) | 46 (64.8) | |
| Letrozole (Femara) | 149 (14.4) | 72 (48.3) | |
| Years since start on AI | 0.02 | ||
| >3 | 270 (25.7) | 121 (44.8) | |
| 1 to 3 | 502 (47.9) | 264 (52.6) | |
| <1 | 277 (26.4) | 158 (57.0) |
AI, aromatase inhibitor. Note: The bold and italicized text indicates a statistically significant P-value of <0.05.